Table 2.

Responses and toxicities to CD8+ enriched young TIL therapya

NMA (n = 33)6Gy TBI (n = 23)Total (n = 56)
Clinical responses (RECIST)
 Nonresponse14 (42%)12 (52%)26 (46%)
 Partial response16 (48%)9 (39%)25 (45%)
 Durations (months)16+, 15+, 14+, 14, 13+, 13, 12, 10, 9, 8, 8, 7, 6, 5, 3, 29+, 8+, 6, 5+, 4+, 4+, 4, 3, 2
 Complete response3 (9%)2 (9%)5 (9%)
 Durations (months)18+,15+,12+5+, 5+
Toxicitiesb
 Positive blood culture0 80 412 (21%)
 Febrile neutropenia (grade 3)171128 (50%)
 Intubation0 20 24 (7%)
 Treatment-related death0 10 12 (4%)
  • aUpdated as of April 1, 2010.

  • bListed once for each patient at the highest grade. Usual IL-2–related toxicities not listed.